All News

This week, the top managed care news included CMS Administrator Seema Verma calling for more disruption to the healthcare system; former FDA Commissioner Scott Gottlieb, MD, reflecting on the agency’s record of innovation; liraglutide demonstrating promise for youth with type 2 diabetes.

Insys Therapeutics’ founder and 4 executives have been found guilty for participating in a scheme that bribed doctors to prescribe its addictive painkiller and misled insurers to pay for the drug; the FDA has approved the first vaccine against dengue fever with some restrictions; Senator Amy Klobuchar, D-Minnesota, has released a $100 billion to combat addiction and improve mental health care.

As expected, HHS Thursday released a final rule implementing a change that would allow healthcare workers to refuse to provide certain services, such as reproductive healthcare, assisted suicide where it is legal, or place children with adoptive families if the parents are gay, lesbian, or transgender, if the service violates their religious or moral beliefs. At the same time, while HHS acknowledged that while some patients may experience some harms from a denial of care, it also proffered a different possibility of how patients could react: they may not mind.

In a study to be presented at the American Academy of Neurology’s annual meeting next week, May 4-10, 2019, in Philadelphia, Pennsylvania, researchers found that the out-of-pocket costs for neurologic medications have increased significantly over the past 12 years, particularly for those enrolled in high-deductible health plans.

Nearly 700 people at California State University and the University of California, both in Los Angeles, were still in quarantine over the weekend after possibly being exposed to measles; the world’s largest seller of cancer drugs, pharma company Roche Holding AG, will lose its top spot with competition from lower-cost drugs, namely biosimilars; findings from a new study showed that blood pressure regulation at or below 130/80 mm Hg lowered the risk of heart attack, stroke, or other complications in patients with type 2 diabetes (T2D).

Sarcoidosis has rarely been reported with polycythemia vera (PV), an acquired myeloproliferative neoplasm characterized by mutant Janus kinase 2 (JAK2) signaling leading to erythrocyte overproduction. In a recent article in the Journal of the American Academy of Dermatology, physicians report on the case of a female patient with PV and sarcoidosis.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text